TPWA
NBIX icon

Twin Peaks Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
+137
New +$18.2K ﹤0.01% 763
2025
Q3 		– Sell
-126
Closed -$16.2K – 1400
2025
Q2 		$16.2K Buy
+126
New +$14.4K 0.01% 681

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Peaks Wealth Advisors's NBIX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 137 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #763 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in NBIX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in NBIX in Q2 2025 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 137 shares of Neurocrine Biosciences worth $18K as of Q1 2026.
  • Neurocrine Biosciences was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #763 holding.
  • Twin Peaks Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.